» Articles » PMID: 20020943

New K-Oximes (K-27 and K-48) in Comparison with Obidoxime (LuH-6), HI-6, Trimedoxime (TMB-4), and Pralidoxime (2-PAM): Survival in Rats Exposed IP to the Organophosphate Paraoxon

Overview
Publisher Informa Healthcare
Specialty Toxicology
Date 2009 Dec 22
PMID 20020943
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

ABSTRACT Oximes are cholinesterase reactivators used in organophosphorus compound poisoning. The purpose of the study was to compare the protective effect of the K-oximes (K-27 and K-48) in male rats with that of obidoxime (LuH-6), trimedoxime (TMB-4), and HI-6, using paraoxon (POX) as a cholinesterase inhibitor. Pralidoxime (2-PAM) was also retested. Seven groups of six rats each were used. Group 1 (G(1)) received 1 mumol/rat POX ( approximately LD(75)), the other groups (G(2-7)) received 1 mumol/rat POX + one of the six reactivators. The animals were monitored for 48 h and time of mortality was recorded. The procedure was repeated seven times. Subsequently, experiments as described were repeated using 10 and 15 mumol/rat POX. Mortality data were compared and hazards ratios (relative risks) ranked with the Cox proportional hazards model using the POX dose and group (reactivator) as time-independent covariables. K-27 followed by K-48 were the most potent reactivators. K-27 was statistically significantly superior to all other reactivators except K-48. The relative risk of death estimated by Cox analysis in K-27- and K-48-treated animals when compared with untreated animals, adjusted for the POX dose, was 0.22 (95% confidence interval [CI], 0.15 to 0.31) and 0.26 (95% CI, 0.18 to 0.37), respectively. We concluded that in the animal model used K-27 and K-48 are superior to older oximes in their ability to protect from paraoxon effects. They should be tested further using methyl- and propyl-organophosphates as toxic agents.

Citing Articles

A complete, evidence-based review on novichok poisoning based on epidemiological aspects and clinical management.

Charejoo A, Arabfard M, Jafari A, Hasani Nourian Y Front Toxicol. 2023; 4:1004705.

PMID: 36762227 PMC: 9905702. DOI: 10.3389/ftox.2022.1004705.


Charged pyridinium oximes with thiocarboxamide moiety are equally or less effective reactivators of organophosphate-inhibited cholinesterases compared to analogous carboxamides.

Kohoutova Z, Malinak D, Andrys R, Svobodova J, Psotka M, Schmidt M J Enzyme Inhib Med Chem. 2022; 37(1):760-767.

PMID: 35193448 PMC: 8881075. DOI: 10.1080/14756366.2022.2041628.


Pd(II) complexes of acetylcholinesterase reactivator obidoxime.

Nedzhib A, Stoykova S, Atanasov V, Pantcheva I, Antonov L Interdiscip Toxicol. 2015; 7(3):139-45.

PMID: 26109891 PMC: 4434107. DOI: 10.2478/intox-2014-0019.


Acetylcholinesterase inhibitors: pharmacology and toxicology.

colovic M, Krstic D, Lazarevic-Pasti T, Bondzic A, Vasic V Curr Neuropharmacol. 2013; 11(3):315-35.

PMID: 24179466 PMC: 3648782. DOI: 10.2174/1570159X11311030006.


Time-dependent changes of oxime K027 concentrations in different parts of rat central nervous system.

Zdarova Karasova J, Zemek F, Musilek K, Kuca K Neurotox Res. 2012; 23(1):63-8.

PMID: 22585538 DOI: 10.1007/s12640-012-9329-4.